The Law Offices of Frank R. Cruz announces an investigation of West Pharmaceutical Services, Inc. (“West” or the “Company”) (NYSE: WST) on behalf of investors concerning the Company’s possible violations of federal securities laws.

What Is The Investigation About?
On February 13, 2025, West issued disappointing revenue and earnings forecasts for 2025, attributing it, in part, to Contract Manufacturing headwinds, including the loss of two major continuous glucose monitoring customers. Additionally, West disclosed that its SmartDose wearable injector devices would be “margin dilutive” in 2025 and that it would be “taking steps to improve [its SmartDose] economics, and all options are on the table.”

On this news, West’s stock price fell $123.17, or 38.2%, to close at $199.11 per share on February 13, 2025, thereby injuring investors.